{"entity":{"id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Mesna in colorectal cancer and prostate cancer, run by CuraCell TX AB, now recruiting.","summary":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC is a phase 1/2 interventional study registered as NCT07255664 by CuraCell TX AB, with 12 participants planned, started 2025-11-13 and due to reach its primary completion in 2027-04. Interventions recorded: CC-38, Pembrolizumab, Cyclophosphamid, Interleukin-2, Uromitexan. Conditions listed: Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07255664","url":"https://clinicaltrials.gov/study/NCT07255664"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","mesna"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07255664","phase":"1/2","setting":"A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer","sponsor":"CuraCell TX AB","enrolled":12,"outcomes":[]},"route":"/trials/nct07255664/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}